Kornimate/medical-research-clean huggingface dataset:
observational study of angiographic coregistered optical coherence tomography in patients undergoing pci

Conditions: Coronary Artery Disease

Summary: to define and evaluate the impact of angiographic coregistered oct on physicians decision-making through prospective data collection in pci procedures.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years. * patient provides signed written informed consent before any study-specific procedure. * patients suffer from coronary artery disease (cad) including at least one angiographically significant (\>70% visual estimation) stenosis present in a native coronary artery with planned pci. exclusion criteria: * subjects with emergent pci or in cardiogenic shock. * subjects with target left main (lm) lesion, with restenosis or stent thrombosis in the target vessel or with aorto-ostial lesion location within 3 mm of the aorta junction (both right and left). * extreme angulation (\> 90°) or excessive tortuosity (\> two 45° angles) proximal to or within the target lesion. * known renal insufficiency (examples being but not limited to estimated glomerular filtration rate (egfr) \< 50 ml/kg/m2, serum creatinine ≥ 2.5 mg/dl or on dialysis). * any other medical condition that in the opinion of the investigator will interfere with patients safety or study results. * currently participating in another clinical study that interferes with study results. * pregnant or nursing subjects and those who plan pregnancy in the period up to 1 year following index procedure. * any condition that precludes the subject from undergoing pci, for example subjects with heparin induced thrombocytopenia, or contrast allergy
transition study: growth hormone therapy in partial growth hormone deficient adolescents

Conditions: Growth Hormone Deficiency

Summary: to evaluate in boys and girls the improvement in body composition under gh treatment in adolescents with co-ghd who remain partially ghd after gh discontinuation.


Eligibility criteria:
inclusion criteria: * males or females : chronological age \> or = 15 years and \< or = 20 years for females * chronological age \> or = 17 years and \< or = 20 years for males * ghd of childhood onset treated for at least 2 years * last gh injection at least 12 months before baseline visit exclusion criteria: * turner's syndrome * chronic hepatic impairment as shown by ggt and / or asat and / or alat \> 2 x uln
an app-based versus a web-based self-management intervention or usual care in people with low back and/or neck pain on a waiting list for hospital-based outpatient rehabilitation

Conditions: Back Pain; Neck Pain

Summary: the purpose of this study is to evaluate the effectiveness of an individually tailored self-management intervention, the selfback app, in improving health status in patients on a waiting list for outpatient rehabilitation due to low back and/or neck pain compared to a non-tailored web-based self-management solution (e-help) and usual care only.

patients on waiting list for treatment at the multidisciplinary outpatient clinic for back, neck and shoulder rehabilitation, st. olavs hospital, trondheim university hospital, norway, due to low back and/or neck pain are the target group for this study. the average waiting time for receiving treatment is 8-10 weeks. the use of digital solutions can be a beneficial approach to support self-management during the waiting period. therefore, the effectiveness of these tools in this patients group needs to be evaluated. a total of 279 participants will be recruited and randomly allocated to one of the three groups: 1) the selfback app in addition to usual care; 2) the e-help webpage in addition to usual care; and 3) usual care only. participants who receive either the selfback app and the e-help webpage will be allowed to seek care, treatment or help elsewhere as usual. self-reported outcome measures will be collected through web-based questionnaires at three follow-up time points: 1) 6 weeks; 2) 3 months (primary endpoint); and 3) 6 months. in addition, participants receiving the selfback app will be asked a set of weekly tailoring questions to individualize self-management plans. objective registry based data linked to social security number in norway will be used to investigate health care consumption and sickness absence at 1 year (and up to 5 years).

Eligibility criteria:
inclusion criteria: * on waiting list for treatment at the multidisciplinary outpatient clinic for back, neck and shoulder rehabilitation, st. olavs hospital, trondheim university hospital, norway due to low back pain and/or neck pain * own and use a smartphone with internet access to download the mobile application * able to provide informed consent exclusion criteria: * less than 4 weeks waiting time until scheduled appointment at clinic (i.e., patients prioritized for urgent treatment/examination) * unable to take part in exercise/physical activity, e.g. non-ambulatory patients, use of walking aids, unable to get up and down the floor independently * unable to speak and/or read norwegian * unable to complete the baseline questionnaire

Keywords: self-management rehabilitation mhealth ehealth
bed rest for idiopathic sudden sensorineural hearing loss

Conditions: Sudden Loss of Hearing

Summary: sudden sensorineural hearing loss: * idiopathic in most cases * 5-20/100,000 new cases annually in the u.s * no establishes pathogenesis * treated with oral steroids in most cases * \~50% improvement in hearing levels * bed rest - acceptable treatment, not well investigated


Eligibility criteria:
inclusion criteria: * patients with sudden sensorineural hearing loss exclusion criteria: * age less than 16 years * contraindication for oral steroid treatment * prior steroid treatment for hearing loss * pregnent women

Keywords: bed rest for idiopathic sudden sensorineural hearing loss
a prospective study of rise for physicians

Conditions: Stress; Burn Out

Summary: the purpose of this study is to determine whether the rise for physicians program has a significant impact on physicians' burnout, resilience, insight, self-compassion, empowerment, and professional and personal mental health and well-being.

this study will include 36 subjects recruited from employed physicians and non-employed physicians with privileges at adventhealth. the study will include data collection along with program participation. program will consist of a 2.5 day retreat facilitated by a licensed mental health professional. data collection will be at 3 timepoints and include 10 surveys that are expected to take 30 minutes to complete.

Eligibility criteria:
inclusion criteria: * adventhealth employed or contract physician * or non-employed physician with adventhealth privileges (hospital, emergency room, or ahmg practice) exclusion criteria: * a resident physician * advanced practice provider * executive leader
a comparison between child-pugh and albumin-bilirubin scores

Conditions: Rupture, Spontaneous; Rupture Liver; Hepatocellular Carcinoma; Hepatic Impairment

Summary: to compare child-pugh and albumin-bilirubin scores in patients with spontaneous rupture of hepatocellular carcinoma

to compare child-pugh and albumin-bilirubin scores in patients with spontaneous rupture of hepatocellular carcinoma. and to determine which is better in predicting long-term survival and short-term survival.

Eligibility criteria:
inclusion criteria: * be diagnosed as hepatocellular carcinoma pathologically; had a tumor rupture confirmed by intraperitoneal exploration or clinical signs and symptoms in combination with imaging examination. exclusion criteria: * be diagnosed as not hepatocellular carcinoma pathologically；had repeated transcatheter arterial chemoembolization(tace) or a long history (more than 1 year) of cancer treatment; loss of follow up or without complete data.

Keywords: spontaneous rupture survival hepatocellular carcinoma child-pugh albumin-bilirubin
a study of continued treatment with regorafenib in participants with solid tumors who have participated in other bayer studies

Conditions: Solid Malignant Tumors

Summary: regorafenib is an anti-cancer drug that blocks several proteins which are involved in the growth of cancer. it has been approved for different types of cancers of the digestive system and is being tested for use in some other solid tumors. cancers that start in an organ, a muscle, or a bone form a solid tumor. this study is for participants with solid tumors who have been taking regorafenib in other bayer studies. they can continue taking regorafenib if it is working when treatment with regorafenib in their previous study ends. the main purpose of this study is to find: * how safe is the continued treatment with regorafenib in participants with solid tumors? * how well is the continued treatment with regorafenib tolerated by participants with solid tumors? participants will continue with the same dose of regorafenib that they were taking in their previous study as long as the treatment works for them/they want to continue the treatment/other medical conditions do not prevent them from participating in the study. for participants that are under 18 years of age, regorafenib tablets will be taken by mouth once daily for 2 weeks and repeat again after a 1-week gap. for participants that are over 18 years of age, regorafenib tablets will be taken by mouth once daily for 3 weeks and repeat again after a 1-week gap. at the start of the study, researchers will review participants' records from the previous study. during the study, researchers will use blood samples and x-rays taken from participants under the age of 18 years to check how safe regorafenib is for children. they will also monitor any medical problems that participants may have during the study. after the last dose, follow-up will be done either within 14 days when participants visit their study doctor or within 30-35 days by phone call. both the researchers and the participants will know the dose of regorafenib the participants receive during the study.


Eligibility criteria:
inclusion criteria: * participant is currently participating in any bayer-sponsored regorafenib study and is receiving regorafenib as study treatment. * participant is currently benefiting from treatment with regorafenib monotherapy. all participants must meet criteria to initiate a subsequent cycle of therapy, as determined by the guidelines of the feeder protocol. * any ongoing adverse events that require temporary treatment interruption must be resolved to baseline grade or assessed as stable and not requiring further treatment interruption by the investigator. exclusion criteria: * ineligibility, for medical reasons, to start the subsequent cycle in the respective feeder study. * participants with a beta-human chorionic gonadotropin (hcg) test result consistent with pregnancy. * participants are using one or more of the prohibited medications listed in the respective feeder study protocol. * participant has been previously permanently discontinued from regorafenib treatment.
non-pharmacological pain management in term neonates

Conditions: Pain

Summary: a randomised clinical trial in a single centre. this study was performed to compare the effect of white noise, facilitated tucking, and their concerted application during heel-stick sampling on pain in term babies. the study was conducted on 90 babies. using stratification and blocking method, 30 babies were included in the white noise group (1st group), 30 in facilitated tucking group (2nd group), and 30 in white noise + facilitated tucking group (3rd group). pain scores of the babies in all groups before, during, and after the procedure were evaluated by two nurses independent from each other using neonatal infant pain scale (nips).

aims and objectives: this study was performed to compare the effect of white noise, facilitated tucking, and their concerted application during heel-stick sampling on pain in term babies. design: a randomised clinical trial in a single centre. methods: the study sample size was determined by the free-software g\* power. based on the power analysis performed prior to the study in order to determine the number of babies to be included in the sample group (with β=0.14087 and α=0.05 risk, power=0.85913), according to the study by karakoc and turker (2014), it was found that 27 neonates should be included in each group. the study was conducted on 90 babies, between july 1, 2017 - august 9, 2017. using stratification and blocking method, 30 babies were included in the white noise group (1st group), 30 in facilitated tucking group (2nd group), and 30 in white noise + facilitated tucking group (3rd group). pain scores of the babies in all groups before, during, and after the procedure were evaluated by two nurses independent from each other using neonatal infant pain scale (nips).

Eligibility criteria:
inclusion criteria: * being term baby * being with mother * being a healthy baby * being able fed orally * being fed at least half an hour before the procedure * being able to draw blood at the first try (since the pain level will change on the second try) * agreed to participate in the study and gave verbal consent were included in the study. exclusion criteria: * having received analgesics and/or sedatives within the last 24 hours * having any complications that prevent pain evaluation (e.g. intracranial hemorrhage, neuromotor growth retardation, etc.) * having undergone any painful procedures within the last hour (e.g. blood drawing, aspiration, ophthalmologic examination, etc.) * prior history of surgery * being connected to mechanical ventilator
dynamics of psychotherapy and treatment outcomes

Conditions: Mental Disorders; Neurotic Disorders; Personality Disorders

Summary: the study is a 3-month controlled trial that aims to measure changes in patient's capacity (mindfulness, resilience, insight, working alliance) and intensity of neurotic symptoms. the following tools are used: the freiburg mindfulness inventory, the psychological insight questionnaire, the connor-davidson resilience scale - short version, the working alliance inventory - short version and the "o" symptom questionnaire. during 12-week group intervention patients are asked to fill in the appropriate set of questionnaires four times (at the beginning, two times between and at the end of treatment). the study is conducted in the psychotherapy unit of university hospital in krakow.


Eligibility criteria:
inclusion criteria: * diagnostic criteria for neurotic disorders (icd-10: f40-f48.9) or personality disorders of mild to moderate severity (icd-10: f60-f61) * obtaining informed consent for participation in the study * being over the age of 18 exclusion criteria: * diagnosis of psychotic and/or organic disorders as well as active addictions

Keywords: therapeutic alliance insight resilience group therapy neurotic symptoms treatment oucome changes in treatment mindfulness process-outcome research
tace-haic plus atezolizumab and bevacizumab for unresectable hcc: a phase 2 clinical trial

Conditions: Hepatocellular Carcinoma

Summary: transartial chemobolization plus hepatic artery infusion chemotherapy showed performance for unresectable hepatocellular carcinoma (hcc). whether the additional of atezolizumab plus bevacizumab will improve the response rate for those patients is still unknown. this phase 2 clinical trial aims to investigate the objective response rate for unresectable hepatocellular carcinoma.


Eligibility criteria:
inclusion criteria: * (a) patients were diagnozied with unresectable hcc, * (b) child-pugh a or b liver function; * (d) eastern cooperative oncology group (ecog) performance status 0-1; * (e) adequate hematologic blood counts (white blood cell count \>3ⅹ109/l, absolute neutrophil count \>1.5ⅹ109/l, platelet count \>10ⅹ109/l, hemoglobin concentration \>85 g/l); exclusion criteria: * (a) severe underlying cardiac, pulmonary, or renal diseases; * (b) history of a second primary malignant tumor; * (c) contraindication to either atezolizumab and bevacizumab.
low concentration ala-pdt in treatment of skin ulcer

Conditions: Skin Ulcer; Photodynamic Therapy

Summary: skin ulcer is a common disease with complicated etiopathogenes, which makes it hard to be cured. it has been reported that photodynamic therapy (pdt) can be used to treat skin ulcers which were caused by different diseases. however, pdt is an expensive treatment and patients always experience obvious pain during or after the treatment, which hinders the application of pdt in skin ulcer. our previous study found that pdt using a low concentration of 5-aminolevulinic acid (ala) could promote the healing of skin ulcer without obvious adverse reactions, which suggests us that low concentration ala-pdt might be an efficient and cost effective treatment in skin ulcer. to further investigate the use of low concentration ala-pdt in skin ulcer, we plan to recruit patients with skin ulcers caused by different diseases, and divide these patients into different groups according to their causes of disease, and then treat them using low concentration ala-pdt to observe the healing process of skin ulcer. this study could further optimize and promote the use of low concentration ala-pdt in skin ulcer.


Eligibility criteria:
inclusion criteria: * chronic skin wounds that involved the dermis and did not heal in three months or did not exhibit a tendency toward healing exclusion criteria: * allergies to photosensitizers and their solvents, serious medical illnesses, such as severe heart disease, severe liver or kidney dysfunction, systemic infection or any concomitant infection that would require treatment with an additional antimicrobial agent, the use of topical or systemic antibiotics within one month prior to treatment. pregnant or lactating women were also excluded.
computed tomography (ct) coronary angiogram evaluation in cancer patients having ct thorax, abdomen and pelvis

Conditions: Coronary Stenosis

Summary: currently patients with certain cancer usually have routine follow up (computed tomography of thorax, abdomen and pelvis) ct tap scans to see response to treatment or relapse. the study proposal allows the evaluation of the coronary arteries by modifying the current ct tap technique without significant additional procedures, intravenous contrast or radiation - i.e. an opportunistic computed tomography coronary angiogram (ctca) without any penalty. the question is does performing computed tomography (ct) of the thorax in such a way confer important additional information about cardiac risk? at the same time the investigators need to ensure that doing scan as per ctca protocol produces equivalent image quality to evaluate other structures in the chest. a recent small retrospective study has using a similar technique suggests that it may in fact improve image quality due to less cardiac related motion artefact.

the study is a non-inferiority observational study to primarily ensure that the computed tomography of thorax, abdomen and pelvis (ct tap) technique produces equivalent image quality of the lungs (hence the need to scan with both conventional technique and the electrocardiograph \[ecg\] gated technique) and secondarily to evaluate the effectiveness of demonstrating the coronary arteries in this cohort of patients who have not received heart rate control.

Eligibility criteria:
inclusion criteria: * patients having routine follow up cancer ct tap scan * age more than or equal to 40 years of age at the time of scan. * able to provide informed written consent * able to hold their breath for at least 10 seconds * has regular heart rate * able to follow verbal commands for breath holding and remain still for the duration of scanning * able to lie supine for the entirety of the scan exclusion criteria: * patient unable to give informed consent. * patients unable to lie supine * patient not able to breath hold for at least 10 seconds. * patients not having regular heart rate. patient with atrial fibrillation or \>2 atrial or ventricular premature beats on a preoperative 12 lead ecg (suboptimal image quality results from irregular heart rhythms) * patient having egfr \<30, to avoid risk of contrast nephrotoxicity in patients potentially at risk) or chronic renal failure on dialysis * patient has known contrast reaction. * patient is pregnant. * patients bmi\>35 * unavailability of research slot to accommodate for the urgency of the scan requested.

Keywords: computed tomography of thorax, abdomen and pelvis cancer patients coronary angiogram evaluation
effect of standardized nutritional therapy on clinical prognosis and cost-effectiveness of inflammatory bowel disease

Conditions: Inflammatory Bowel Disease

Summary: to construct a standardized stepped nutritional treatment process for inpatients with inflammatory bowel disease, including nutritional risk screening and assessment, standardized nutritional treatment implementation, therapeutic effect follow-up and monitoring, family nutritional treatment follow-up, etc.

nutrition therapy of inflammatory bowel disease should follow the principle of sequential treatment of nutrition, which is the preferred scheme with enteral nutrition, from slow to fast, from weak to strong, from the elements to the whole protein on the steps of the gradual transition, in order to improve enteral nutrition in patients with tolerance and compliance and improve patient quality of life and long-term survival rate, reduce the social burden of disease, patients with good economic and social benefits.

Eligibility criteria:
inclusion criteria: * patients diagnosed with inflammatory bowel disease exclusion criteria: * nothing
do emotions and pain combined affect mechanical pain thresholds and other pain-related variables

Conditions: Pain Thresholds

Summary: the purpose of this study is to investigate if different emotional states could influence mechanical pain thresholds and other pain - related variables such as pain tolerance, pain intensity and pain - related negative affect.

participants will be randomized into 4 different groups watching different short video-clips (2.20 min), while at the same time experience short-lasting, experimentally induced pain. the negative emotions group will watch an uncomfortable short video containing violence and blood, the positive emotions group will watch a video containing a stand-up comedy show, the neutral emotions group will watch a video about how to paint a house, and the control group will just wait for 2.20 min, without any instructions about what to think about. pressure pain thresholds will be measured with an algometer before and after the video-clip combined with experimental pain interventions.

Eligibility criteria:
inclusion criteria: * above 18 years of age * fluent in swedish. exclusion criteria: * pain anywhere in body during the test session * known neurological disease.

Keywords: pressure pain thresholds pain emotions
cohort study on treatment of cardiovascular diseases with traditional chinese medicine

Conditions: Cardiovascular Diseases

Summary: this is a cohort study performed in patients with cardiovascular diaeases who were treated with oral chinese medicine and western medicine. collect indicators such as the incidence of cardiovascular events, all due to readmission, all due to death. to hospital using clinical samples to detect genomics, proteomics, metabolomics, intestinal flora and sclerotia.to explore the clinical efficacy of chinese patent medicine in the treatment of cardiovascular diseases, and provide reliable data support for its clinical application.


Eligibility criteria:
inclusion criteria: all patients admitted to the department of cardiovascular medicine at the first teaching hospital of tianjin university of traditional chinese medicine, the second teaching hospital of tianjin university of traditional chinese medicine, tianjin chest hospital, tianjin hospital of itcwm nankai hospital and tianjin academy of traditional chinese medicine affiliated hospital were considered for inclusion in this study, and all western medical diagnoses were identified and classified according to the international classification of diseases, 11th revision (icd-11). exclusion criteria: no exclusion criteria.